The U.S. Food and Drug Administration has approved Eli Lilly's Foundayo, a once-daily oral medication for weight management, broadening patient access to GLP-1 treatments. The pill is expected to begin shipping immediately, offering a convenient alternative to weekly injectable drugs that have dominated the obesity treatment landscape.
Foundayo, known generically as orforglipron, works as a GLP-1 receptor agonist, a class of drug that mimics gut hormones to regulate appetite and food intake. In a late-stage clinical trial, patients who stayed on the treatment lost an average of 12.4% of their body weight. While this is less than the weight loss associated with Lilly's own injectable Zepbound, which often exceeds 20%, company leadership emphasizes the pill's role in improving accessibility. "It's more accessible, it's easier to fit into your daily routine," said Eli Lilly CEO Dave Ricks.
The launch positions Lilly in direct competition with Novo Nordisk, which recently introduced its own oral version of Wegovy. The two rivals are now competing on convenience, price, and specific drug attributes. Foundayo can be taken at any time of day without food restrictions, whereas the Wegovy pill must be taken first thing in the morning on an empty stomach. On price, the companies are aligned for cash-paying customers, with the lowest doses of both pills starting at $149 per month. For insured patients, Lilly offers a coupon program that could lower the monthly cost to $25.
The Strategic Shift to Oral Treatments
Industry analysts see the approval as a strategic move to capture a different segment of the market. The pill format is expected to attract patients who are hesitant about injections or who are seeking a maintenance therapy after achieving weight loss goals with a more potent shot. Furthermore, as a small-molecule drug, Foundayo is simpler to manufacture and distribute globally than peptide-based injectables, which require complex production and cold-chain logistics. Lilly expects to secure regulatory approvals in more than 40 countries within the next year.
Looking ahead, the focus will be on patient adoption and how the oral drug expands the overall obesity treatment market. Early prescription data for Novo's pill suggests it is drawing in new patients rather than converting existing ones from injections, a trend Lilly anticipates will continue. The company's significant manufacturing investments, totaling over $55 billion since 2020, are designed to ensure scalable supply. With Medicare Part D coverage for obesity drugs beginning this summer and a more potent triple-hormone shot, retatrutide, in late-stage trials, Lilly is building a comprehensive portfolio aimed at offering patients multiple choices for their health goals.